BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3259251)

  • 1. Modulation of immune functions by long-term treatment with recombinant interferon-alpha 2 in a patient with hairy-cell leukemia.
    Teichmann JV; Sieber G; Ludwig WD; Ruehl H
    J Interferon Res; 1988 Feb; 8(1):15-24. PubMed ID: 3259251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive effects of recombinant interferon-alpha during long-term treatment of cancer patients.
    Teichmann JV; Sieber G; Ludwig WD; Ruehl H
    Cancer; 1989 May; 63(10):1990-3. PubMed ID: 2702571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological recovery and dose evaluation in IFN-alpha treatment of hairy cell leukemia: analysis of leukocyte differentiation antigens, NK and 2',5'-oligoadenylate synthetase activity.
    Nielsen B; Hokland M; Justesen J; Hasselbalch H; Ellegaard J; Hokland P
    Eur J Haematol; 1989 Jan; 42(1):50-9. PubMed ID: 2914594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of alpha-interferon on the immune system of patients with hairy cell leukemia.
    Foa R; Fierro MT; Lusso P; Bonferroni M; Raspadori D; Buzzi M; Zinzani PL; Resegotti L; Lauria F
    Leukemia; 1987 Apr; 1(4):377-9. PubMed ID: 3499543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of interferon-alpha on the expression and release of the CD23 molecule in hairy cell leukemia.
    Genot E; Sarfati M; Sigaux F; Petit-Koskas E; Billard C; Mathiot C; Falcoff E; Delespesse G; Kolb JP
    Blood; 1989 Nov; 74(7):2455-63. PubMed ID: 2529929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The beneficial effects of alpha-interferon in hairy cell leukemia are not attributable to NK cell-mediated cytotoxicity.
    Griffiths SD; Cawley JC
    Leukemia; 1987 Apr; 1(4):372-6. PubMed ID: 3669763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole blood assay for NK activity in splenectomized and non-splenectomized hairy cell leukemia patients during IFN-alpha-2b treatment.
    Nielsen B; Hokland P; Ellegaard J; Hasselbalch H; Hokland M
    Leuk Res; 1989; 13(6):451-6. PubMed ID: 2770329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-interferon activates the natural killer system in patients with hairy cell leukemia.
    Semenzato G; Pizzolo G; Agostini C; Ambrosetti A; Zambello R; Trentin L; Luca M; Masciarelli M; Chilosi M; Vinante F
    Blood; 1986 Jul; 68(1):293-6. PubMed ID: 3719101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms accounting for the defective natural killer activity in patients with hairy cell leukemia.
    Trentin L; Zambello R; Agostini C; Ambrosetti A; Chisesi T; Raimondi R; Bulian P; Pizzolo G; Semenzato G
    Blood; 1990 Apr; 75(7):1525-30. PubMed ID: 2317560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia.
    Urba WJ; Baseler MW; Kopp WC; Steis RG; Clark JW; Smith JW; Coggin DL; Longo DL
    Blood; 1989 Jan; 73(1):38-46. PubMed ID: 2783373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the optimal dose and the mode of action of alpha-interferon in the treatment of hairy cell leukemia.
    Huber C; Aulitzky W; Tilg H; von Lüttichau I; Troppmair J; Nachbauer K; Gastl G
    Leukemia; 1987 Apr; 1(4):355-7. PubMed ID: 3669762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon alpha-2 for hairy cell leukemia: evidence for induction of RNA synthesis in hairy cells and failure to correlate enhancement of natural killer cells with elimination of hairy cells.
    Schwarzmeier JD; Schwabe M; Prischl F; Wagner L; Lion T; Micksche M; Köller U
    Eur J Haematol; 1987 Nov; 39(5):418-25. PubMed ID: 3691760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hairy cell leukemia associated with large granular lymphocyte leukemia: immunologic and genomic study, effect of interferon treatment.
    Marolleau JP; Henni T; Gaulard P; Le Couedic JP; Gourdin MF; Divine M; Katz A; Tulliez M; Goossens M; Reyes F
    Blood; 1988 Aug; 72(2):655-60. PubMed ID: 2840988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-interferon induces remission in hairy cell leukemia without enhancement of natural killing.
    Gastl G; Aulitzky W; Leiter E; Flener R; Huber C
    Blut; 1986 May; 52(5):273-9. PubMed ID: 3635416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-cell growth factor-induced and alpha-interferon-inhibited proliferation of hairy cells coincides with modulation of cell surface antigens.
    Gamliel H; Brownstein BH; Gurfel D; Wu SH; Rosner MC; Golomb HM
    Cancer Res; 1990 Jul; 50(13):4111-20. PubMed ID: 2354460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin 2- and interferon alpha induced natural killer cell activity as a marker of progression in hairy cell leukemia.
    Bigda J; Mysliwska J; Baran W; Hellmann A; Mysliwski A
    Leuk Lymphoma; 1993 Mar; 9(4-5):371-6. PubMed ID: 8348073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-interferon activated cytotoxic lymphocytes in hairy cell leukemia patients: evaluation of cytotoxic events.
    Trentin L; Ambrosetti A; Zambello R; Agostini C; Masciarelli M; Vinante F; Chilosi M; Pizzolo G; Cetto G; Semenzato G
    Leuk Res; 1987; 11(9):843-7. PubMed ID: 3499539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity.
    Chilosi M; Semenzato G; Cetto G; Ambrosetti A; Fiore-Donati L; Perona G; Berton G; Lestani M; Scarpa A; Agostini C
    Blood; 1987 Nov; 70(5):1530-5. PubMed ID: 3117133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy.
    Vedantham S; Gamliel H; Golomb HM
    Cancer Res; 1992 Mar; 52(5):1056-66. PubMed ID: 1737364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hairy cell leukemia cells are relatively NK-insensitive targets.
    Starling GC; Nimmo JC; Hart DN
    Pathology; 1988 Oct; 20(4):361-5. PubMed ID: 2977221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.